Back to results
US 2026/0097127 A1Published application
Multimeric T-Cell Modulatory Polypeptides and Methods of Use Thereof
AssigneeCue Biopharma, Inc.
InventorsSaso Cemerski, Rodolfo J. Chaparro, Ronald D. Seidel, III, John F. Ross
Life of this patent
Estimating the term…
Abstract
The present disclosure provides T-cell modulatory multimeric polypeptides that comprise an immunomodulatory polypeptide and that comprise an epitope-presenting Wilms tumor peptide. A T-cell modulatory multimeric polypeptide is useful for modulating the activity of a T cell, and for modulating an immune response in an individual.
Claims1
A T-cell modulatory multimeric polypeptide comprising:
- at least one heterodimer comprising:
- a) a first polypeptide comprising:
- i) a Wilms tumor-1 (WT-1) peptide epitope comprising the amino acid sequence X1X2X3TWNQMNL (SEQ ID NO:460) or X2X3TWNQMNL (SEQ ID NO:461), wherein each of X1, X2, and X3 is independently any amino acid, with the proviso that the N-terminal amino acid is not a Cys, and wherein the WT-1 peptide epitope has a length from 9 to 25 amino acids;
- and
- ii) a first Class I major histocompatibility complex (MHC) polypeptide;
- b) a second polypeptide comprising a second class I MHC polypeptide, and
- c) at least one activating immunomodulatory polypeptide,
- wherein the first and/or the second polypeptide comprises the at least one immunomodulatory polypeptide, and optionally wherein the first or the second polypeptide comprises an immunoglobulin (Ig) Fc polypeptide.
5 more elements
Dependencies are inferred from the claim text.